Inari Medical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin Strange
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 6001 Oak Canyon Irvine CA United States of America 92618
- IPO Date
- May 22, 2020
- CIK
- 0001531048
- Website
- inarimedical.com
- Similar Companies
- Business
- Inari Medical, Inc., a medical device company focused on developing minimally invasive catheter-based thrombectomy systems to treat venous thromboembolism and related vascular conditions, operates as a subsidiary of Stryker Corporation following its acquisition in February 2025. Founded in 2011 and headquartered in Irvine, California, the company offers a comprehensive portfolio of purpose-built products including the FlowTriever system for lytic-free pulmonary embolism treatment; ClotTriever system and ClotTriever XL catheter for deep vein thrombosis and vena cava thrombectomy; RevCore thrombectomy catheter for venous in-stent thrombosis; InThrill thrombectomy system for arteriovenous fistula thrombosis; Artix thrombectomy system, launched in March 2025, for peripheral arterial thromboembolism; Protrieve sheath and Intri24 introducer sheath for venous access; FlowSaver blood return system; FlowStasis; VenaCore; and Inari-branded retrieval and support devices. Inari Medical serves interventional physicians, hospitals, and patients globally, with operations spanning the United States, Europe, and a December 2024 joint venture in Greater China through VFLO with partners 6 Dimensions Capital and 120 Capital to expand access to its VTE technologies. Recent strategic developments include the $4.9 billion acquisition by Stryker, completed on February 19, 2025, which complements Stryker's neurovascular portfolio and accelerates Inari's endovascular capabilities; the Artix system launch as its first arterial thrombectomy entry; and ongoing clinical trials such as PEERLESS II to support product adoption.
If You Could Only Hold 3 Investments for Life, Consider These
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Investors to Learn More About the Investigation
Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Stockholders to Connect
Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Shareholders to Learn More About the Investigation
Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Are You Looking for a Top Momentum Pick? Why Inari Medical, Inc. (NARI) is a Great Choice